Category - Developments

Developments

Eckert & Ziegler to supply POINT Biopharma with Actinium-225

A subsidiary of POINT Biopharma Global (NASDAQ:PNT) signed an agreement for the supply of Actinium-225 (non-carrier-added Ac-225) from Eckert & Ziegler Strahlen EUZ (ETR) of Germany for POINT’s pipeline of next...

April 4, 2023

Developments

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...

April 3, 2023

Developments

Tonix presents positive Phase 3 data in fibromyalgia

Tonix Pharmaceuticals (NASDAQ:TNXP) presented a poster at the 5th International Congress on Controversies in Fibromyalgia in Vienna that its TNX-102 SL met its pre-specified primary endpoint in the Phase 3 RELIEF trial...

March 30, 2023

Developments

Bolt posts positive Phase 1 data in HER2-expressing tumors

Bolt Biotherapeutics (NASDAQ:BOLT) reported positive topline data from its recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies. Topline...

March 30, 2023

Developments

Cognition presents proteomic biomarker data in Alzheimer’s

Cognition Therapeutics (NASDAQ:CGTX) presented results of a meta-analysis from the first cohort of 24 participants in the Phase 2 SHINE trial and the complete dataset from the Phase 1b SPARC studies in adults with mild...

March 28, 2023

Developments

NeuroSense, Mass General to collaborate on PrimeC in ALS

NeuroSense Therapeutics (NASDAQ:NRSN) signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, Ph.D., and Massachusetts General Hospital’s NeuroEpigenetics lab to explore the neurotherapeutic effects of...

March 27, 2023

Developments

EyePoint completes enrollment in Phase 2 wet AMD trial

EyePoint Pharmaceuticals (NASDAQ:EYPT) completed enrollment in the Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance...

March 27, 2023

Developments

Vistagen posts positive Phase 3 open-label study of fasedienol in SAD

Vistagen (NASDAQ:VTGN) reported positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of fasedienol (PH94B) over time in...

March 22, 2023

Developments

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...

March 22, 2023

Developments

Hepion to highlight AI-POWR platform at AI webinar

Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...

March 17, 2023

Category - Developments

General

More